A date for your diary: the next course an "Update on Pharmacoeconomics in the Irish Healthcare Setting" will take place on 15th & 16th May 2019 in Dublin Castle. Places now available.
Following assessment of the applicant’s submission the NCPE recommends that alectinib (Alecensa®), for the first line treatment of adult patients with ALK-positive advanced NSCLC, not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments. This recommendation should be considered while also having regard to the criteria
The NCPE recommends that lesinurad not be considered for reimbursement. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.